Bluebird names oncology spinoff, establishes leadership team

Bluebird bio has disclosed the name of its oncology spinoff: 2seventy bio. The spinoff is taking cancer therapies and some executives, including the CEO and chief scientific officer, from bluebird.

Massachusetts-based bluebird first shared details of its plans to spin off its cancer assets into a new publicly traded company in January. Bluebird framed the separation as the way to best support both its cancer and rare disease assets given differences in the expertise needed to develop, manufacture and win approval for candidates in each space.